ADVANCED PHARMACOLOGY FINAL
EXAM (NR565) (VERIFIED AND
CORRECT Q & A) SATISFACTION
GUARANTEED 2026/2027
CHAMBERLAIN
1. A patient with a history of heart failure is prescribed a medication that increases
myocardial contractility by inhibiting the Na+/K+-ATPase pump. Which electrolyte
abnormality increases the risk of toxicity for this drug?
A. Hypercalcemia
B. Hyperkalemia
C. Hypokalemia
D. Hyponatremia
Answer: C
Conceptual Explanation: Digoxin inhibits the Na+/K+-ATPase pump. Low potassium
(hypokalemia) increases digoxin binding to the pump, significantly increasing the risk of
toxicity.
2. Which of the following describes ‘first-pass metabolism’ in pharmacology?
A. The excretion of a drug through the kidneys on the first cycle of blood flow.
,B. The binding of a drug to plasma proteins during initial circulation.
C. The rapid uptake of a drug by the lungs before reaching systemic circulation.
D. The metabolic breakdown of an orally administered drug in the liver before it reaches
systemic circulation.
Answer: D
Conceptual Explanation: First-pass metabolism occurs when the concentration of a drug
is greatly reduced before it reaches the systemic circulation, typically by the liver after oral
administration.
3. A patient taking Warfarin is prescribed Amiodarone for atrial fibrillation. What is the
expected interaction between these two drugs?
A. Amiodarone induces CYP2C9, leading to a decrease in INR.
B. Warfarin increases the metabolism of Amiodarone, reducing its antiarrhythmic effect.
C. Amiodarone decreases the absorption of Warfarin in the GI tract.
D. Amiodarone inhibits CYP2C9, leading to an increase in INR.
Answer: D
Conceptual Explanation: Amiodarone is a potent inhibitor of CYP2C9, the primary
enzyme that metabolizes Warfarin. This leads to higher levels of Warfarin and a significant
increase in the International Normalized Ratio (INR), increasing bleeding risk.
, 4. What is the primary mechanism of action for ACE inhibitors in the treatment of
hypertension?
A. Increasing the breakdown of bradykinin in the lungs.
B. Directly inhibiting the release of Renin from the juxtaglomerular cells.
C. Antagonizing the Angiotensin II Type 1 receptor.
D. Blocking the conversion of Angiotensin I to Angiotensin II.
Answer: D
Conceptual Explanation: ACE inhibitors prevent the conversion of Angiotensin I to the
potent vasoconstrictor Angiotensin II by inhibiting the Angiotensin-Converting Enzyme.
5. Which medication is contraindicated in a patient with a history of Medullary Thyroid
Carcinoma (MTC)?
A. Metformin
B. Empagliflozin
C. Sitagliptin
D. Liraglutide
Answer: D
Conceptual Explanation: GLP-1 receptor agonists like Liraglutide carry a black box
warning regarding the risk of thyroid C-cell tumors and are contraindicated in patients
EXAM (NR565) (VERIFIED AND
CORRECT Q & A) SATISFACTION
GUARANTEED 2026/2027
CHAMBERLAIN
1. A patient with a history of heart failure is prescribed a medication that increases
myocardial contractility by inhibiting the Na+/K+-ATPase pump. Which electrolyte
abnormality increases the risk of toxicity for this drug?
A. Hypercalcemia
B. Hyperkalemia
C. Hypokalemia
D. Hyponatremia
Answer: C
Conceptual Explanation: Digoxin inhibits the Na+/K+-ATPase pump. Low potassium
(hypokalemia) increases digoxin binding to the pump, significantly increasing the risk of
toxicity.
2. Which of the following describes ‘first-pass metabolism’ in pharmacology?
A. The excretion of a drug through the kidneys on the first cycle of blood flow.
,B. The binding of a drug to plasma proteins during initial circulation.
C. The rapid uptake of a drug by the lungs before reaching systemic circulation.
D. The metabolic breakdown of an orally administered drug in the liver before it reaches
systemic circulation.
Answer: D
Conceptual Explanation: First-pass metabolism occurs when the concentration of a drug
is greatly reduced before it reaches the systemic circulation, typically by the liver after oral
administration.
3. A patient taking Warfarin is prescribed Amiodarone for atrial fibrillation. What is the
expected interaction between these two drugs?
A. Amiodarone induces CYP2C9, leading to a decrease in INR.
B. Warfarin increases the metabolism of Amiodarone, reducing its antiarrhythmic effect.
C. Amiodarone decreases the absorption of Warfarin in the GI tract.
D. Amiodarone inhibits CYP2C9, leading to an increase in INR.
Answer: D
Conceptual Explanation: Amiodarone is a potent inhibitor of CYP2C9, the primary
enzyme that metabolizes Warfarin. This leads to higher levels of Warfarin and a significant
increase in the International Normalized Ratio (INR), increasing bleeding risk.
, 4. What is the primary mechanism of action for ACE inhibitors in the treatment of
hypertension?
A. Increasing the breakdown of bradykinin in the lungs.
B. Directly inhibiting the release of Renin from the juxtaglomerular cells.
C. Antagonizing the Angiotensin II Type 1 receptor.
D. Blocking the conversion of Angiotensin I to Angiotensin II.
Answer: D
Conceptual Explanation: ACE inhibitors prevent the conversion of Angiotensin I to the
potent vasoconstrictor Angiotensin II by inhibiting the Angiotensin-Converting Enzyme.
5. Which medication is contraindicated in a patient with a history of Medullary Thyroid
Carcinoma (MTC)?
A. Metformin
B. Empagliflozin
C. Sitagliptin
D. Liraglutide
Answer: D
Conceptual Explanation: GLP-1 receptor agonists like Liraglutide carry a black box
warning regarding the risk of thyroid C-cell tumors and are contraindicated in patients
